Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8321152 | 0.87 | TDP1 (0.49) | TDP1ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5745815 | 0.87 | TDP1 (0.52) | TDP1ALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL7373604 | 0.87 | TDP1 (0.50) | TDP1ALDH1A1KMT2ANPC1L3MBTL1 | |
| SCHEMBL5755198 | 0.86 | RAB9A (0.56) | TDP1DRD1ALDH1A1MEN1KMT2A | |
| SCHEMBL5749934 | 0.86 | TDP1 (0.72) | TDP1DRD1ALDH1A1MEN1KMT2A | |
| SCHEMBL20818012 | 0.81 | TDP1 (1.00) | TDP1ALDH1A1KMT2AMAPK8GAA | |
| SCHEMBL3174045 | 0.80 | TDP1 (0.67) | TDP1DRD1ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL5750322 | 0.79 | RAB9A (0.59) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL9122123 | 0.79 | TDP1 (0.66) | TDP1MEN1KMT2AMAPT | |
| SCHEMBL5753712 | 0.78 | RAB9A (0.47) | ALDH1A1MEN1KMT2ANPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | TDP1 1674/4885DRD1 836/4885ALDH1A1 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.